Dialysis Industry Spends Big To Protect Profits
Dialysis companies are fighting a bill in the California legislature that could disrupt their business model. Their weapons: campaign cash and a sophisticated public relations campaign.
The independent source for health policy research, polling, and news.
1,521 - 1,540 of 1,879 Results
Dialysis companies are fighting a bill in the California legislature that could disrupt their business model. Their weapons: campaign cash and a sophisticated public relations campaign.
Before âMedicare for All,â there was just Medicare, the federal program that provides insurance to 60 million Americans. This week, KHNâs Julie Rovner talks to Tricia Neuman of the Kaiser Family Foundation about how Medicare works and whom it serves. Then, Joanne Kenen of Politico, Paige Winfield Cunningham of The Washington Post and Kimberly Leonard of the Washington Examiner join Rovner to talk about some current Medicare issues being debated in Washington, D.C.
Americans routinely skirt federal law by crossing into Canada and Mexico or tapping online pharmacies abroad to purchase prescription medications at a fraction of the price they would pay at home. Is it safe? Not necessarily. Hereâs some advice.
An encounter with a cat led to rabies shots and provided yet another illustration of how confusing, contrary and expensive the American health care system is.
The loss of the longtime hospital in Fort Scott, Kan., forces trauma patients to deal with changing services and expectations.
You asked about drug prices, the âCadillac taxâ on generous insurance plans and why Americans donât know that most other countries also have combination public-private insurance systems. This week, Anna Edney of Bloomberg News, Alice Miranda Ollstein of Politico and Caitlin Owens of Axios join KHNâs Julie Rovner to answer those questions.
Critics worry the delays come at a steep cost: Medicare paying for millions of unnecessary exams and patients subject to radiation for no medical benefit.
States increasingly expect to see insurers enter or re-enter ACA marketplaces next year. Thatâs a critical sign that these exchanges are growing less risky for insurers despite ongoing political and legal battles over the ACA.
In the wake of the opioid crisis, the highly communicable hepatitis A virus is spreading in more than half the states and making its way into the general public. Underfunded health officials are valiantly trying to fight it with vaccines.
Medicare beneficiaries under observation care in the hospital can face higher costs for treatment and are not covered for nursing home care when discharged. A federal trial in Hartford, Conn., will determine whether the governmentâs ban on appeals involving observation care coverage is fair.
The patient is from Mississippi. The surgeon is from Wisconsin. They meet in a Mexican resort for knee replacement surgery. Because the care costs so much less than in the U.S, the patientâs health plan pays her $5,000.
Residents in Colorado ski resort country found relief from high insurance premiums and high hospital costs by joining forces and negotiating prices directly with the local hospital.
Tennessee's innovative Medicaid program is offering bonuses to mental health providers who help make sure their Medicaid patients get preventive help and treatment for physical ailments, too.
The recent tragic mass shootings have refocused efforts to treat gun violence as a public health issue rather than strictly a law enforcement problem. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico and Mary Agnes Carey of Kaiser Health News join KHNâs Julie Rovner to discuss this, plus the health implications of the budget deal passed by Congress and signed by President Donald Trump, as well as reaction from Canada to a proposal to allow broader imports of its prescription drugs. Plus, for âextra credit,â the panelists recommend their favorite health stories of the week.
The drug CroFab, which has been on the market since 2000, now faces competition from a drug called Anavip. But both are expensive.
A federal advisory panel says people between ages 27 and 45 may benefit from the vaccine to fight the human papillomavirus. But some public health advocates worry that the advice doesnât provide doctors and patients clear guidance about who in this large age group are good candidates for the vaccine.
A case of questionable logic.
After journalists investigate, Fresenius, one of the largest dialysis providers in the U.S., has agreed to waive a half-million-dollar bill. Sovereign Valentine, from Plains, Mont., said itâs a âhuge relief.â
KHNâs Julie Rovner appears on CSPANâs Washington Journal Tuesday and compares two key health programs being touted by Democratic presidential candidates: âMedicare for Allâ and an optional government health plan, often called a public option.
Known as âauthorized generics,â in-house spinoffs of brand-name drugs quietly undermine the competition.
Š 2026 KFF